Abstract:Lacking an effective mechanism to safely and consistently enhance macromolecular uptake across the intestinal epithelium, prospects for successful development of oral therapeutic peptide drugs remain unlikely. We previously addressed this challenge by identifying an endogenous mechanism that controls intestinal paracellular permeability that can be activated by a peptide, termed PIP 640, which can increase cellular levels of phosphorylated myosin light chain at position S19 (MLC-pS19). Apical application in vitro or luminal application in vivo was shown to increase macromolecular solute transport within minutes that recovered completely within a few hours after removal. We now examine the nature of PIP 640-mediated permeability changes. Confluent Caco-2 cell monolayers treated with PIP 640 enhanced apical-to-basolateral (AB) transport of 4-kDa, but not 10-kDa, dextran. Expression and/or cellular distribution changes of tight junction (TJ) proteins were restricted to increased claudin-2 over a time course that correlated with an apparent shift in its distribution from the nucleus to the membrane fraction of the cell. PIP 640-mediated epithelial changes were distinct from the combined actions of the pro-inflammatory cytokines tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ). While TNF-α/IFN-γ treatment also increased MLC-pS19 levels, these cytokines enhanced AB transport for 70-kDa dextran and decreased occludin expression at TJs. Claudin-2-dependent changes induced by PIP 640 resulted in an AB transport bias for positively-charged macromolecules demonstrated in vitro using charge variants of 4-kDa dextrans and by comparing transport of salmon calcitonin to exenatide. Comparable outcomes of increased TJ localization of claudin-2 and enhanced transport of these therapeutic peptides that biased toward cationic characteristics was demonstrated in vivo following after intra-luminal injection into rat jejunum. Together, these data have shown a potential mechanism for PIP 640 to enhance paracellular permeability of solutes in the size range of small therapeutic peptides that is biased toward positively-charged solutes.

Paracellular Delivery of Protein Drugs with Smart EnteroPatho Nanoparticles

An intestinal paracellular pathway biased toward positively-charged macromolecules

Mechanisms of Nanoparticle Transport across Intestinal Tissue: An Oral Delivery Perspective

Polymeric nanoparticle drug delivery technologies for oral delivery applications

Polymeric nanoparticles for oral delivery of biopharmaceuticals: an overview

Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model

Transmucosal Delivery of Peptides and Proteins Through Nanofibers: Current Status and Emerging Developments

A Novel Intracellular Protein Delivery Platform Based on Single-Protein Nanocapsules

Oral peptide and protein delivery: intestinal obstacles and commercial prospects

Cell-penetrating peptides for transmucosal delivery of proteins

Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies

Nanocarriers for intracellular delivery of proteins in biomedical applications: strategies and recent advances

Angiopep-2-functionalized nanoparticles enhance transport of protein drugs across intestinal epithelia by self-regulation of targeted receptors.

Custom protein nanoparticles for targeted drug delivery

Enhancement of Oral Bioavailability of Protein and Peptide by Polysaccharide-based Nanoparticles

Nanocarriers for Protein Delivery to the Cytosol: Assessing the Endosomal Escape of Poly(Lactide-co-Glycolide)-Poly(Ethylene Imine) Nanoparticles

Oral Delivery of Protein Drugs via Lysine Polymer‐Based Nanoparticle Platforms

Engineered Escherichia coli for the in situ secretion of therapeutic nanobodies in the gut

Recent Advances in Oral and Transdermal Protein Delivery Systems

Enzyme‐Triggered Intestine‐Specific Targeting Adhesive Platform For Universal Oral Drug Delivery

Protein Nanoparticles: Promising Platforms for Drug Delivery Applications